Carradori et al. (2022) focused their research on MAO inhibitors and identified several promising candidates for the treatment of neurodegenerative disorders such as PD, with compound 4 displaying particularly high selectivity against MAO-B [286]. Here, MAOB is linked to Parkinson disease.